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Summary
Among dominant neurodegenerative disorders, Hunting-
ton’s disease (HD) is perhaps the best candidate for treat-
ment with small interfering RNAs (siRNAs) [1–9]. Invariably
fatal, HD is caused by expansion of a CAG repeat in the Hun-
tingtin gene, creating an extended polyglutamine tract that
makes the Huntingtin protein toxic [10]. Silencing mutant
Huntingtin messenger RNA (mRNA) should provide thera-
peutic benefit, but normal Huntingtin likely contributes to
neuronal function [11–13]. No siRNA strategy can yet distin-
guish among the normal and disease Huntingtin alleles and
other mRNAs containing CAG repeats [14]. siRNAs targeting
the disease isoform of a heterozygous single-nucleotide
polymorphism (SNP) in Huntingtin provide an alternative
[15–19]. We sequenced 22 predicted SNP sites in 225 human
samples corresponding to HD and control subjects. We find
that 48% of our patient population is heterozygous at a single
SNP site; one isoform of this SNP is associated with HD.
Several other SNP sites are frequently heterozygous. Conse-
quently, five allele-specific siRNAs, corresponding to just
three SNP sites, could be used to treat three-quarters of
the United States and European HD patient populations.
We have designed and validated selective siRNAs for the
three SNP sites, laying the foundation for allele-specific
RNA interference (RNAi) therapy for HD.
Results
Current strategies for designing single-nucleotide-selective
small interfering RNAs (siRNAs) rely on SNPs that produce
a purine:purine mismatch between the siRNA guide strand
and the counter-selected messenger RNA (mRNA) target
*Correspondence: phillip.zamore@umassmed.edu (P.D.Z.), neil.aronin@
umassmed.edu (N.A.)[15, 20]. Only 4 of the 12 nucleotide mismatches satisfy this
criterion. Even when purine:purine mismatches are available,
single-mismatch siRNAs vary in their selectivity, ranging in
one study, for example, from 4.3- to 133-fold discrimination
between the fully complementary targeted RNA and the
mismatched, counter-selected RNA [15].
Sequencing and Analysis of Huntingtin SNP Sites
in HD and Control Patients
We sequenced 12 PCR amplicons spanning 22 known single-
nucleotide polymorphism (SNP) sites in Huntingtin by using
genomic DNA from 109 Huntington’s disease (HD) patients
and 116 non-HD controls (Figure 1A). The sequenced DNA
encompassed six complete coding exons and the portion of
exon 67 that contains the stop codon and part of the 30
untranslated region (UTR). Twenty-two of the SNP sites were
reported in the SNPper database [21, 22]. Four of these
reported SNP sites were present only as a single isoform in
our population. We identified an additional two sites by rese-
quencing exons 2–67 in the Huntingtin locus from six HD
patient samples. Table 1 reports the frequency of heterozy-
gosity for each SNP site for patient and control DNA.
Of the 24 SNPs, rs362307 at nucleotide (nt) 9633 (exon 67)
of the mRNA was significantly associated with HD (p =
0.0000523). After Bonferroni correction for multiple testing,
the association remained significant (p = 0.000890). More
than 48% of the HD patients that we examined—which are
believed to be representative of the US and European patient
pool—were heterozygous at this site (Table 1). The U isoform
of the rs362307 SNP comprised 26% of Huntingtin alleles
among the patients that we tested, but only 6% of alleles
among the controls. This finding suggests that a single,
allele-specific siRNA selectively targeting the U mRNA isoform
of this SNP could be used to treat nearly half of this patient
population. To confirm our statistical analysis, we used a previ-
ously reported method to determine the rs362307 SNP isoform
linked to the CAG repeat expansion allele [23] for 16 patient
blood samples. Of the 16 patients, 8 were heterozygous at
this site; of the 8, the U isoform was linked to the expanded
CAG repeat for 7 patients (Table S1 available online). We
conclude that the U isoform of this SNP is associated with
the disease allele of Huntingtin mRNA.
An Additional Two SNPs Achieve Patient Coverage > 75%
Eight other SNP sites were each heterozygous in > 33% of our
patient population but did not show a statistically significant
association with HD. Because no particular isoform of these
SNPs is associated with HD in our patient population, each
SNP site requires two distinct, isoform-selective siRNAs. We
calculated the maximum coverage (i.e., the number of patients
with at least one heterozygous SNP site) for all possible combi-
nations of one to seven SNPs. Adding two additional SNP sites
covered w75% of our patient population. Using four or more
SNP sites as potential targets for siRNA therapy is not
predicted to provide much additional benefit; using even
seven SNP sites achieves < 80% coverage but would require
13 isoform-selective siRNAs (Figure 1B).
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775Figure 1. Analysis of SNPs in the Human Huntingtin mRNA
(A) We sequenced PCR amplicons from genomic DNA from 109 HD patients and 116 controls spanning 22 SNP sites within the Huntingtin mRNA. The SNP
at nucleotide 9633 (rs362307, shown in red) is associated with HD, and sites for which we have designed siRNAs are in bold.
(B) The maximum percentage of patients to have at least one heterozygous SNP with any combination of one to seven SNPs was calculated with the
experimentally determined frequency of heterozygosity for the SNP sites in our study. Three SNPs coverw75% of the patient population analyzed here.Development of Allele-Specific siRNAs
The HD-associated SNP site at position 9633 of the Huntingtin
mRNA does not fall into the category of SNPs that are pre-
dicted to be readily amenable to selective targeting because
it does not create a purine:purine mismatch between siRNA
and mRNA [15, 20]. However, our analysis of Huntingtin
SNPs in HD patients and controls (Figure 1B and Table 1)
suggests that a practicable RNA-silencing therapy for HD
requires an siRNA that targets the disease isoform at this
site but spares the normal Huntingtin mRNA. To this end, we
designed siRNAs targeting the U isoform of the position 9633
SNP. We tested both the efficacy and selectivity of the siRNAs
in cultured human HeLa cells cotransfected with the siRNA
and luciferase reporters containing in their 30 UTRs either the
U or C isoform of the sequence containing the SNP. In our
hands, such luciferase reporter assays are good predictors
of the efficacy and selectivity of siRNAs for endogenous
mRNA targets. Figures S1 and S2 present an example with
a pair of siRNAs—one fully matched and one bearing a position
10 (P10) mismatch—that targets an SNP site (rs363125) in
endogenous Huntingtin mRNA in HeLa cells. Previous work
has shown that such SNP-selective siRNAs can reduce mutant
Huntingtin levels while leaving normal Huntingtin intact [24].
siRNAs whose guide strand was fully matched to the U iso-
form, which is associated with HD but mismatched at position
10 or position 16 to the C isoform, were functional but failed to
discriminate between U and C reporter mRNAs (Figure S3A).
(siRNAs that bear purine:pyrimidine mismatches to their coun-
terselected targets generally show poor discrimination [15].)We also tested single mismatches at positions 2 through 9
(Table S2) but found that all of these were less specific than
the most selective position 10 + seed mismatch. Double-
mismatch strategies based on a position 16 mismatch with
the counterselected isoform had very low activity (Table S2).
Previous work has shown that adding a second mismatch
can improve the ability of siRNA to discriminate between alleles
[25]. We reasoned that adding a mismatch in the seed sequence
of the siRNA might sufficiently destabilize our siRNA so that the
doubly mismatched siRNA would lose its ability to silence
the wild-type Huntingtin mRNA, and pairing at the SNP site
would allow the singly mismatched siRNA to retain silencing
activity for the disease allele. Therefore, we tested doubly mis-
matched siRNAs combining a seed mismatch with a position 10
mismatch. We prepared siRNAs that are predicted to mismatch
at position 10 with the normal Huntingtin mRNA and that also
bear an additional mismatch to both normal and disease alleles
at one of the six seed positions (2–7). Mismatches at positions
5 or 6, combined with a position 10 mismatch with the counter-
selected isoform, resulted in a reduction or loss of silencing of
the SNP-mismatched target while retaining good activity
against the SNP-matched target (Figure S3B).
Table 2 reports ‘‘discrimination ratios’’—the ratio of the IC50 of
the siRNA for the counterselected target to the IC50 of the tar-
geted mRNA. The P10 (SNP) + P5 siRNA (IC50P10 mismatch > 20;
IC50P10 match = 0.62 6 0.43 nM) had a discrimination ratio > 32
and, at 20 nM, the highest concentration tested, reduced
expression of the counterselected reporter by only 33%. The
P10 + P6 siRNA achieved no appreciable reduction in
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776Table 1. Frequency of Heterozygosity for 24 SNP Sites in the Huntingtin mRNA
Percent Heterozygosity
Location in mRNA (Position, nt) Reference Number Controls HD Patients
ORF, exon 20 (2822) rs363075 G/A, 10.3% (G/G, 89.7%) G/A, 12.8% (G/G, 86.2%; A/A, 0.9%)
ORF, exon 25 (3335) rs35892913 G/A, 10.3% (G/G, 89.7%) G/A, 13.0% (G/G, 86.1%; A/A, 0.9%)
ORF, exon 25 (3389) rs1065746 G/C, 0% (G/G, 100%) G/C, 0.9% (G/G, 99.1%)
ORF, exon 25 (3418) rs17781557 T/G, 12.9% (T/T, 87.1%) T/G, 1.9% (T/T, 98.1%)
ORF, exon 29 (3946) rs4690074 C/T, 37.9% (C/C, 50.9%; T/T, 11.2) C/T, 35.8% (C/C, 59.6%; T/T, 4.6%)
ORF, exon 39 (5304) rs363125 C/A, 17.5% (C/C, 79.0%; A/A, 3.5%) C/A, 11.0% (C/C, 87.2%; A/A, 1.8%)
ORF, exon 44 (6150) exon 44 (new) G/A, 0% (G/G, 100%) G/A, 2.8% (G/G, 97.2%)
ORF, exon 48 (6736) rs362336 G/A, 38.7% (G/G, 49.6%; A/A, 11.7%) G/A, 37.4% (G/G, 57.9%; A/A, 4.7%)
ORF, exon 50 (7070) rs362331 T/C, 45.7% (T/T, 31.0%; C/C, 23.3%) T/C, 39.4% (T/T, 49.5%; C/C, 11.0%)
ORF, exon 57 (7942) rs362273 A/G, 40.3% (A/A, 48.2%; G/G, 11.4%) A/G, 35.2% (A/A, 60.2%; G/G, 4.6%)
ORF, exon 61 (8501) rs362272 G/A, 37.1% (G/G, 51.7%; A/A, 11.2%) G/A, 36.1% (G/G, 59.3%; A/A, 4.6%)
ORF, exon 65 (9053) rs3025806 A/T, 0% (C/C, 100%) A/T, 0% (C/C, 100%)
ORF, exon 65 (9175) exon 65 (new) G/A, 2.3% (G/G, 97.7%) G/A, 0% (G/G, 100%)
ORF, exon 67 (9523) rs362308 T/C, 0% (T/T, 100%) T/C, 0% (T/T, 100%)
30UTR, exon 67 (9633)a rs362307 C/T, 13.0% (C/C, 87.0%) C/T, 48.6% (C/C, 49.5%; T/T, 1.9%)
30UTR, exon 67 (9888) rs362306 G/A, 36.0% (G/G, 52.6%; A/A, 11.4%) G/A, 35.8% (G/G, 59.6%; A/A, 4.6%)
30UTR, exon 67 (9936) rs362268 C/G, 36.8% (C/C, 50.0%; G/G 13.2%) C/G, 35.8% (C/C, 59.6%; G/G, 4.6%)
30UTR, exon 67 (9948) rs362305 C/G, 20.2% (C/C, 78.1%; G/G 1.8%) C/G, 11.9% (C/C, 85.3%; G/G, 2.8%)
30UTR, exon 67 (10060) rs362304 C/A, 22.8% (C/C, 73.7%; A/A, 3.5%) C/A, 11.9% (C/C, 85.3%; AA, 2.8%)
30UTR, exon 67 (10095) rs362303 C/T, 18.4% (C/C, 79.8%; T/T, 1.8%) C/A, 11.9% (C/C, 85.3%; T/T, 2.8%)
30UTR, exon 67 (10704) rs1557210 C/T, 0% (C/C, 100%) C/T, 0% (C/C, 100%)
30UTR, exon 67 (10708) rs362302 C/T, 4.3% (C/C, 95.7%) C/T, 0% (C/C, 100%)
30UTR, exon 67 (10796) rs3025805 G/T, 0% (G/G, 100%) G/T, 0% (G/G, 100%)
30UTR, exon 67 (11006) rs362267 C/T, 36.2% (C/C, 52.6%; T/T, 11.2%) C/T, 35.5% (C/C, 59.8%; T/T, 4.7%)
The SNP sites for which we tested siRNAs are in italics.
a These siRNAs provide good discrimination at the HD-associated SNP site.expression of the mismatched reporter, even at 20 nM
(IC50P10 mismatch > 20 nM), but was less effective against the
matched reporter (IC50P10 match = 1.560.31 nM), yielding a lowerdiscrimination ratio. We often observed such a trade-off
betweentheefficacy and theselectivity ofSNP-specific siRNAs.
We also designed and tested an siRNA targeting the C isoform;Table 2. Validation of siRNAs Designed to Distinguish between Matched and Mismatched SNP Isoforms
IC50 (nM)
Reference











rs363125 50-agcguugaaguacugucccca-30 10 G:A none none 0.17 6 0.11 0.27 6 0.25 1.6
rs363125 50-agcguugaauuacugucccca-30 10 U:C none none 0.18 6 0.09 0.22 6 0.07 1.2
rs363125 50-ucuucuagcguugaaguacug-30 16 G:A none none 0.36 6 0.24 >20 >55
rs363125 50-ucuucuagcguugaauuacug-30 16 U:C none none 0.74 6 0.40 >20 >27
rs362307 50-cacaagggcgcagacuuccaa-30 10 G:U none none 0.36 6 0.04 0.77 6 0.16 2.1
rs362307 50-uacaagggcacagacuuccaa-30 10 A:C none none 0.16 6 0.09 0.14 6 0.10 0.87
rs362307 50-gcagggcacaagggcgcagac-30 16 G:U none none 0.73 6 0.12 0.72 6 0.12 0.99
rs362307 50-ucagggcacaagggcacagac-30 16 A:C none none 0.19 6 0.02 0.20 6 0.06 1.1
rs362307 50-cgcaagggcacagacuuccaa-30 10 A:C 2 G:U 1.0 6 0.35 1.9 6 0.27 1.9
rs362307 50-cauaagggcacagacuuccaa-30 10 A:C 3 U:G 3.0 6 1.8 3.5 6 1.6 1.2
rs362307 50-caccagggcacagacuuccaa-30 10 A:C 4 C:U 1.0 6 0.22 1.6 6 1.2 1.6
rs362307 50-cacacgggcacagacuuccaa-30 10 A:C 5 C:U 0.62 6 0.43 >20 >32
rs362307 50-cacaauggcacagacuuccaa-30 10 A:C 6 U:C 1.5 6 0.31 >20 >13
rs362307 50-cacaagugcacagacuuccaa-30 10 A:C 7 U:C 1.3 6 0.51 5.9 6 1.9 4.5
rs362307 50-cacaauggcgcagacuuccaa-30 10 G:U 6 U:C 3.2 6 2.2 >20 >6
rs362273 50-guugaucuguagcagcagcuu-30 10 U:G none none 0.09 6 0.14 0.01 6 0.006 0.11
rs362273 50-guugaucugcagcagcagcuu-30 10 C:A none none 0.12 6 0.06 0.44 6 0.11 3.7
rs362273 50-cucgggguugaucuguagcag-30 16 U:G none none 0.01 6 0.002 0.007 6 0.002 0.70
rs362273 50-cucgggguugaucugcagcag-30 16 C:A none none 0.01 6 0.003 0.004 6 0.001 0.41
rs362273 50-ucugaucuguagcagcagcuu-30 10 U:G 2 C:A 0.01 6 0.002 0.06 6 0.008 5.9
rs362273 50-uucgaucuguagcagcagcuu-30 10 U:G 3 C:A 0.02 6 0.003 0.29 6 0.04 15
rs362273 50-uuuuaucuguagcagcagcuu-30 10 U:G 4 U:C 0.03 6 0.006 0.37 6 0.11 11
rs362273 50-uuugcucuguagcagcagcuu-30 10 U:G 5 C:U 0.02 6 0.003 0.59 6 0.08 31
rs362273 50-uuugaccuguagcagcagcuu-30 10 U:G 6 C:A 0.02 6 0.002 0.06 6 0.015 2.7
rs362273 50-uuugauuuguagcagcagcuu-30 10 U:G 7 U:G 0.006 6 0.001 0.10 6 0.02 17
rs362273 50-uuugcucugcagcagcagcuu-30 10 C:A 5 C:U 0.15 6 0.04 0.74 6 0.11 4.9
IC50 values are given as the average6 SD for at least three independent experiments. The IC50 is reported as > 20 nM for siRNAs that failed to achieve half-
maximal inhibition at the highest concentration tested. Underline indicates the site of the primary mismatch; italics indicate the site of the secondary
mismatch.
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it selectively targeted the P10-matched allele (IC50P10 mismatch >
20; IC50P10 match = 3.26 2.2 nM) (Figure S3C and Table 2).
To cover 75% of HD patients requires siRNAs targeting addi-
tional SNPs. Because no specific nucleotide isoform of these
SNP sites is associated with HD, selective siRNAs are needed
for both isoforms. Our long-term strategy would be to screen
patients to determine the SNP isoform associated with the
expanded CAG repeat Huntingtin allele [23] and select the cor-
responding siRNA for therapy. As a first step toward this goal,
we tested each siRNA’s ability to target one isoform of the
SNP while minimizing silencing of the other isoform. For the
SNP site rs363125, which lies at nt 5304 (exon 39) and occurs
as either an A or a C, a single mismatch was sufficient to provide
a high degree of selectivity for the fully matched target for both
the A (>27-fold discrimination; IC50mismatch > 20 nM; IC50match =
0.7460.40 nM) and C (IC50mismatch > 20 nM; >55-fold discrimina-
tion; IC50match = 0.3660.24 nM) isoforms (Figures 2A and S4 and
Table2). Fora secondSNP, rs362273,which liesatnt 7942 (exon
57) in theHuntingtinmRNA and occurs as either an A or a G, the
P10 (SNP) + P5 siRNA design targeting the A isoform of the SNP
providedw30-fold selectivity (IC50P10 mismatch = 0.596 0.08 nM;
IC50P10 match = 0.02 6 0.003 nM), whereas the siRNA targeting
the G isoform (IC50P10 mismatch = 0.746 0.11 nM; IC50P10 match =
0.15 6 0.04 nM) gavew4.9-fold selectivity (Figures 2B and S5
and Table 2).
Discussion
Targeted reduction of mutant Huntingtin mRNA is considered
an ideal strategy for treating HD. The primary obstacles to the
Figure 2. Representative Data for the Develop-
ment of Isoform-Specific siRNAs Targeting Two
Additional SNP Sites
(A) siRNAs mismatched at position 16 discrimi-
nated between luciferase reporter mRNAs
bearing either the C or the A isoform of the
rs363125 SNP site.
(B) siRNAs bearing a mismatch to the SNP site
at position 10 and an additional position 5
mismatch discriminated between the G and A
isoforms of the rs362273 SNP site.
development of such a therapy have
been concerns about the number of siR-
NAs that would require testing in clinical
trials. It is not clear whether drug regula-
tory agencies will permit patient-specific
siRNAs to be used in humans without
large-scale clinical trials. Such trials
are, of course, not possible if only small
numbers of patients share a common
SNP isoform. Our results suggest that
there is sufficient heterozygosity at
a small number of SNP sites among
American and European HD patients to
support SNP-specific siRNA therapy.
Targeting just three SNPs with five
siRNAs should cover the majority of HD
patients in the population studied here.
This is possible because of the presence
of several highly heterozygous SNPs
and because a single SNP isoform for
SNP rs362307 is associated with HD. In a parallel study, Hay-
den and colleagues likewise report that SNP rs362307 is asso-
ciated with HD [26]. One siRNA targeting this HD-associated
isoform should target the mutant Huntingtin allele in nearly
50% of our patient population. We have developed an siRNA
that selectively targets the disease-associated isoform of
this SNP in cultured human cells. In the near future, preclinical
testing of this siRNA for efficacy, selectivity, and safety is
clearly of the highest importance.
What of the w25% of patients predicted to be beyond the
reach of the five siRNAs developed here? Unfortunately, our
analysis predicts that a very large number of siRNAs will be
required to provide siRNA therapy for this subpopulation.
Adding an additional four siRNAs (for a total of nine siRNAs
corresponding to five SNP sites) only increases the treatable
patient population by 3%. A further increase in the number of
siRNAs provides no real additional benefit.
Finally, we find that, by using potentiating mismatches in the
seed sequence, isoform-selective siRNAs can be designed for
SNP sites predicted to be poor candidates for the development
of allele-selective siRNAs. Our data suggest that a single siRNA
directed against a SNP isoform associated with HD could be
used to treat nearly half of the US and European HD population.
Clearly, an siRNA directed against this SNP isoform, such as
the siRNA presented here, merits thorough preclinical valida-
tion to test its promise as a candidate therapy for HD.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures, five
figures, and three tables and can be found with this article online at http://
www.cell.com/current-biology/supplemental/S0960-9822(09)00878-1.
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